You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
強化疫苗業務研發能力和後續產品儲備 復星醫藥(02196.HK)擬控股收購安特金
格隆匯 10-26 20:32

格隆匯10月26日丨復星醫藥(02196.HK)發佈公吿,為豐富集團疫苗產品管線,在已有的病毒性疫苗產品基礎上,拓展細菌性疫苗產品儲備,控股子公司復星醫藥產業擬以現金和所持大連雅立峯100%股權(大連雅立峯系病毒性疫苗研發生產企業)作價控股收購安特金(細菌性疫苗研發生產企業)。

於本次收購中,復星醫藥產業擬(1)以現金合計約人民幣110,803.38萬元受讓安特金相關股東持有的安特金共計人民幣1,039.6766萬元的註冊資本(約佔緊鄰本次收購交割前安特金註冊資本總額的32.52%、緊隨本次收購交割後安特金註冊資本總額的13.01%)(即本次轉讓),及(2)以持有的大連雅立峯100%股權作價人民幣289,800萬元認繳安特金新增註冊資本人民幣4,795.8605萬元(佔緊隨本次收購交割後安特金註冊資本總額的60.00%)(即本次增資)。本次收購完成後,復星醫藥產業將持有安特金約73.01%的股權,並通過安特金持有大連雅立峯100%的股權(即復星醫藥產業對大連雅立峯享有的權益比例將由本次收購前的100%減少至約73.01%)。

安特金成立於2012年7月,註冊地為四川省成都天府國際生物城,法定代表人為趙光輝。安特金是一家專注於細菌性疫苗產品研發和生產的企業,擁有多糖-蛋白多價結合專利,並應用於在研的13價肺炎球菌結合疫苗、24價肺炎球菌結合疫苗。

如安特金在研的13價肺炎球菌結合疫苗(PCV13)、24價肺炎球菌結合疫苗(PCV24)均達到相關約定的臨牀里程碑,後續轉讓賣方有權於2026年12月31日或之前依約要求復星醫藥產業受讓該等賣方屆時持有的不超過1,502.7567萬元的安特金註冊資本(約佔緊隨本次收購交割後安特金註冊資本總額的18.80%),受讓總價不超過人民幣141,003.67萬元。若後續轉讓頂格完成後,復星醫藥產業將至多持有安特金約91.81%的股權、復星醫藥產業對大連雅立峯享有的權益比例將增加至約91.81%。

公司表示,安特金是一家擁有獨特多糖—蛋白多價結合專利技術的疫苗研發生產企業,專注於細菌性疫苗的研發。其具有自主知識產權的13價肺炎球菌多價結合疫苗即將開展III期臨牀試驗、24價肺炎球菌多價結合疫苗即將開展I期臨牀試驗,同時正積極佈局ACHib結合型流腦疫苗等產品的研發。安特金在細菌性疫苗的研發能力和產品儲備方面與公司控股子公司雅立峯的病毒性疫苗產品線可形成互補和協同。本次收購完成後,有利於強化集團疫苗業務的研發能力和後續產品儲備。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account